NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00988208,Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer,https://clinicaltrials.gov/study/NCT00988208,Mainsail,COMPLETED,"The purpose of the study is to determine whether lenalidomide is safe and effective for use in combination with docetaxel and prednisone for the treatment of subjects with metastatic Castrate-Resistant Prostate Cancer.

The addition of lenalidomide to docetaxel and prednisone is proposed to increase the life expectancy of these subjects.",YES,Prostate Cancer,DRUG: Lenalidomide|DRUG: Docetaxel|DRUG: Prednisone|DRUG: Placebo,"Overall Survival (OS), Overall survival (OS) was the time from the date of randomization to the date of death from any cause. If no death was reported for a participant before the cut-off date for OS analysis, OS was censored at the last date at which the participant was alive. The median OS was calculated based on Kaplan-Meier estimates and corresponding 95% confidence interval (CI) was calculated using the method provided by Brookmeyer and Crowley., From randomization until death from any cause up to the cut-off date of 13 January 2012; up to approximately 26 months","Progression-Free Survival (PFS), PFS was the time from randomization to disease progression, or death, whatever occurred first. Progression criteria was met by analysis of target and non-target lesions as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters while on study or the appearance of one or more new lesions; an increase of at least 5mm as a total sum. Lymph nodes identified as target lesions (≥ 15 mm diameter in short axis) will be followed and reported by changes in diameter of short axis; or the unequivocal progression of a non-target lesion defined as an increase in the overall disease burden based on the change in non-measurable disease that is comparable in scope to the increase required to declare PD for measurable disease; Two or more new bone lesions as detected by bone scan, From randomization until disease progression or death from any cause; up to the cut-off date of 13 Jan 2012; maximum time on study was approximately 26 months|Percentage of Participants With an Objective Response According to Response Evaluation Criteria in Solid Tumors - RECIST Version 1.1 Criteria, Objective response (OR) is defined as having complete response (CR) or partial response (PR) as best overall response based on RECIST Criteria 1.1 and defines a CR = Disappearance of all target lesions except lymph nodes (LN); LN must have a decrease in the short axis to \<10mm; PR = 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters; Progressed Disease (PD) = 20% increase in sum of diameters of target lesions taking as a reference the smallest sum of diameters and an absolute increase of ≥5 mm; the appearance of ≥1 new lesions; Stable Disease (SD)= Neither shrinkage to qualify for PR nor increase to qualify for PD taking the smallest sum diameters on study as reference. For non-target lesions a CR = Disappearance of all non-target lesions and all LN must be non-pathological in size \<10 mm; Non-CR/Non PD: persistence of one or more non-target lesions; PD = unequivocal progression of existing non-target lesions or appearance of new ones, From day 1 to data cut-off 13 January 2012; maximum time on study was approximately 26 months|Number of Participants With Treatment Emergent Adverse Events (AEs), A TEAE is defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. A TESAE is defined as any serious adverse event (SAE) occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. Safety and severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0; Severity of AEs were graded (including second primary malignancies) as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5-Fatal;, From the time from of first dose of study drug administration to 28 days after the last dose of study drug and up to the data cut off date of 13 January 2012; the maximum duration of study drug was 93 weeks for DP and 90.6 weeks for DPL|Percentage of Participants Who Received Post-Study Therapies, Percentage of Participants Who Received Post-Study Therapies for advanced Prostate Cancer., The date when the first consent form was signed to the last date of AE data collection;up to 5 years; up to the date of the final data analysis date of 20 April 2017|Percentage of Participants With Secondary Primary Malignancies During the Course of the Trial, Second primary malignancies were monitored as events of interest and reported as serious adverse events throughout the course of the trial., The date when the first consent form was signed to the last date of AE data collection; up to the date of the final data analysis date of 30 November 2016; 7 years and 19 days|Time to Onset of Secondary Primary Malignancies, Time of Onset of Secondary Primary Malignancies was considered an event of interest, The date when the first consent form was signed to the last date of AE data collection; up to the date of the final data analysis date of 30 November 2016; 7 years and 19 days",,Celgene,,MALE,"ADULT, OLDER_ADULT",PHASE3,1059,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",CC-5013-PC-002|EudraCT Number 2008-007969-23,2009-11-11,2012-01-13,2016-11-28,2009-10-02,2013-09-05,2018-04-04,"Hematology Oncology Associates, Phoenix, Arizona, 85012, United States|Northern AZ Hematology and Oncology Assoc, Sedona, Arizona, 86336, United States|Arizona Oncology, Tucson, Arizona, 85710, United States|City of Hope Cancer Center, Duarte, California, 91010-3000, United States|Southwest Cancer Center - Escondido, Escondido, California, 92025, United States|Scripps Cancer Center - Clinical Research, La Jolla, California, 92037, United States|VA Long Beach Healthcare System, Long Beach, California, 90822, United States|The Angeles Clinc and Research Institute, Los Angeles, California, 90025, United States|University of Southern California, Los Angeles, California, 90033, United States|Prostate Oncology Specialists, Marina Del Rey, California, 90292, United States|Stanford University Medical Center, Stanford, California, 94035-5821, United States|Rocky Mountain Cancer Centers-Colorado Springs Circle, Colorado Springs, Colorado, 80909, United States|Washington Cancer Institute, Washington, District of Columbia, 20010, United States|Melbourne Internal Medicine Associates, Melbourne, Florida, 32901, United States|Advanced Medical Specialties, Miami, Florida, 33176, United States|Florida Cancer Institute - New Hope, New Port Richey, Florida, 34655, United States|Ocala Oncology Center, Ocala, Florida, 34474, United States|Cancer Centers of Florida, P.A.- West Gore Street, Orlando, Florida, 32806, United States|South Florida Oncology - Hematology, Tamarac, Florida, 33321, United States|Palm Beach Cancer Institute, LLC, West Palm Beach, Florida, 33401, United States|Cancer Care and Hematology Specialists of Chicagoland, Niles, Illinois, 60714, United States|Lutheran General Hospital, Park Ridge, Illinois, 60068, United States|Indiana University Health, Indianapolis, Indiana, 46219, United States|Hematology and Oncology Specialist, LLC, Metairie, Louisiana, 70006, United States|Maryland Oncology Hematology PA, Columbia, Maryland, 21044, United States|Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, 55404, United States|Missouri Cancer Associates, Columbia, Missouri, 65201, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89169, United States|Summit Medical Group Overlook Oncology Center, Berkeley Heights, New Jersey, 07922, United States|Hematology-Oncology Associates of NNJ, P, Morristown, New Jersey, 07960, United States|Hematology Oncology Associates of South Jersey, Mount Holly, New Jersey, 08060, United States|New York Oncology Hematology P.C., Albany, New York, 12208, United States|Columbia Univ Medical Center, New York, New York, 10032, United States|Weill Cornell Medical College Dr. Feldman's Office, New York, New York, 10065, United States|New Bern Cancer Care, New Bern, North Carolina, 28562, United States|Cancer Centers of North Carolina, Raleigh, North Carolina, 27607, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, 58501, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, 45242, United States|Northwest Cancer Specialists-Tualatin, Tualatin, Oregon, 97062, United States|Ralph H. Johnson VA Medical Center, Charleston, South Carolina, 29401, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, 29210, United States|Cancer Center of the Carolinas, Greer, South Carolina, 29650, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, 37404, United States|Cookeville Regional Medical Center, Cookeville, Tennessee, 38501, United States|Sarah Cannon Research Institute UK, Nashville, Tennessee, 37203-1632, United States|Texas Oncology, P.A.-Amarillo, Amarillo, Texas, 79106, United States|Texas Oncology-Arlington South, Arlington, Texas, 76014, United States|Texas Oncology, PA, Austin, Texas, 78758, United States|Baylor Sammons Cancer Center, Dallas, Texas, 75246, United States|Texas Oncology, P.A.-Fort Worth, Fort Worth, Texas, 76104, United States|Longview Cancer Center, Longview, Texas, 75601, United States|Allison Cancer Center, Midland, Texas, 79701, United States|Texas Oncology, P.A. - Paris, Paris, Texas, 75460, United States|Southlake Oncology, Southlake, Texas, 76092, United States|Texas Oncology, P.A. - Tyler, Tyler, Texas, 75702, United States|Texas Oncology Deke Slayton Cancer Center, Webster, Texas, 77598, United States|Texas Oncology-Texoma Cancer Center, Wichita Falls, Texas, 76310, United States|Veterans Education and Research Association of Northern New England, Inc., White River Junction, Vermont, 05009, United States|Cancer Outreach Associates, Abingdon, Virginia, 24211, United States|Fairfax Northern Virginia Hematology Oncology, Fairfax, Virginia, 22031, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Virginia Cancer Institute, Richmond, Virginia, 23230, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., Roanoke, Virginia, 24014, United States|Columbia Basin Hematology and Oncology, Kennewick, Washington, 99336, United States|VA Puget Sound HCS Seattle Division, Seattle, Washington, 98108-1532, United States|Evergreen Hematology and Oncology, Spokane, Washington, 99218, United States|Royal Adelaide Hospital, Adelaide, South Australia, SA 5000, Australia|Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia|Flinders Medical Centre, Bedford Park, 5042, Australia|Chris O'Brien Lifehouse, Camperdown, NSW 2050, Australia|Sir Charles Gairdner Hospital, Nedlands, 6009, Australia|Port Macquarie Base Hospital, Port Macquarie, NSW 2444, Australia|Redcliffe Hospital, Redcliffe, QLD 4020, Australia|Royal North Shore Hospital, St Leonards, 2065, Australia|Newcastle Calvary Mater Hospital, Waratah, 2298, Australia|Westmead Hospital, Westmead, NSW 2145, Australia|Border Medical Oncology, Wodonga, 3690, Australia|The Queen Elizabeth Hospital, Woodville South, 5011, Australia|Princess Alexandra Hospital, Woolloongabba, QLD 4102, Australia|Medical University of Graz, Graz, 8036, Austria|Landeskrankenhaus Salzburg, Salzburg, 5020, Austria|Krankenhaus der Barmherzigen Brueder, Vienna, 1020, Austria|Medizinische Universitat Wien, Vienna, 1090, Austria|ZNA Middelheim, Antwerpen, 2020, Belgium|Hopital Erasme, Brussels, 1070, Belgium|Edith Cavell Clinic, Bruxelles, 1180, Belgium|AZ Groeninge, Kortrijk, 8500, Belgium|UZ Leuven, Leuven, 3000, Belgium|AZ Nikolaas, Sint-Niklaas, 9100, Belgium|The Health Institute for Men CMX Research Inc, Toronto, Ontario, M1P 2T7, Canada|Les Urologues Specialises, Montreal, Quebec, H2X 1N8, Canada|Krajska zdravotni, a.s. Nemocnice Chomutov, o.z., Chomutov, 430 12, Czechia|Fakultni nemocnice Motol, Prague 5, 150 06, Czechia|Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad La, Usti Nad Labem, 40113, Czechia|Arhus Universitets hospital, Aarhus C, 8000, Denmark|Herlev Hospital, Herlev, 2730, Denmark|Rigshospitalet University Hospital, Kobenhavn, 2100, Denmark|Odense Universitetshospital, Odense C, 5000, Denmark|CRLCC Paul Papin, Angers 49, 49933, France|Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux, 33076, France|Centre Georges Francois Leclerc, Dijon Cedex, 21079, France|Clinique Victor Hugo, Le Mans, 72000, France|Centre Oscar Lambret, Lille 59, 59020, France|Centre Leon Berard, Lyon, 69373, France|Clinique de Valdegour, Nimes, 30900, France|CHU de Poitiers, Poitiers Cedex, 86021, France|Centre Eugene Marquis, Rennes Cedex, 35042, France|CRLCC Centre Rene Gauducheau, Saint Herblain 44, 44805, France|Institut de Cancerologie de la Loire, Saint Priest En Jaroz, 42270, France|Hopital Civil de Strasbourg, Strasbourg, 67091, France|CHRU Hopital Bretonneau, Tours Cedex, 37044, France|Institut Gustave Roussy, Villejuif, 94805, France|Vivantes Klinikum am Urban, Berlin, 10967, Germany|Medizinisches Zentrum Bonn-Friedensplatz, Bonn, 53111, Germany|Diakonissenkrankenhaus Dessau gGmbH, Dessau-Rosslau, 06846, Germany|Universitaetsklinikum Duesseldorf, Duesseldorf, 40225, Germany|Krankenhaus Nordwest, Frankfurt a.M., 60488, Germany|Onkologische Praxis Freiburg, Freiburg, 79106, Germany|Universitatsklinikum Hamburg-Eppendorf / IVDP, Hamburg, 20246, Germany|IORC- Innovation Onkologie Research and Consulting GmbH, Hamburg, 22081, Germany|Praxis fuer Haematologie und Onkologie Koblenz, Koblenz, 56068, Germany|Vituro GmbH & Co KG, Leipzig, 4277, Germany|TU München - Klinikum rechts der Isar, München, 81675, Germany|Universitaetsklinikum Muenster, Münster, 48149, Germany|University-Hospital Tübingen, Tuebingen, 72076, Germany|Universitatsklinikum Ulm, Ulm, 89075, Germany|Alexandra General Hospital of Athens, Athens, 11528, Greece|Agioi Anargyroi Hospital, Athens, 14564, Greece|University Hospital of Larissa, Larissa, 41110, Greece|Papageorgiou General Hospital of Thessaloniki, Thessaloniki, 56429, Greece|Fovarosi Onkirmanyzat Peterfy S.Utcai Korhaz-Rend.Int es Baleseti Kozp., Budapest, 1076, Hungary|Fovarosi Onkormanyzat Bajcsy-Zsilinszky Korhaz es Rendelointezet, Budapest, 1106, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc, 3526, Hungary|Pecsi Tudomanyegytem Altalanos Orvostudomanyi Kar, Pecs, 7623, Hungary|The Soroka University Medical Center, Beer Sheva, 84101, Israel|Rambam Health Care Campus, Haifa, 31096, Israel|Rabin Medical Center, Petach Tikva, 49100, Israel|Assaf Harofeh Medical Center, Zerifin, 70300, Israel|Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, 70124, Italy|Ordine Mauriziano, Candiolo, 10023, Italy|Azienda Ospedaliera Istituti Ospitalieri di Cremona, Cremona, 23100, Italy|Ospedale Vito Fazzi, Lecce, 73100, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.), Meldola, 47014, Italy|Ospedale di Mirano, Mirano (VE), 30035, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, 56126, Italy|Ospedale degli Infermi di Rimini, Rimini, 47900, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, 00149, Italy|Azienda Ospedaliero-Universitaria Santa Maria della Miserico, Udine, 70124, Italy|Hospital Angeles Lindavista, D.f, Df, 07760, Mexico|Consultorio de Especialidad en Urologia Privado, Durango, DGO, 34000, Mexico|Hospital Fatima, Sinaloa, SIN, 81200, Mexico|Consultorio Privado- Dr Jose Arturo Rodriguez Rivera, Zapopan, JAL, 45040, Mexico|VU University Medical Center VU Medisch Centrum, Amsterdam, 1081 HV, Netherlands|Ziekenhuis Rijnstate, Arhem, 6800 TA, Netherlands|Amphia Ziekenhuis Molengracht, Breda, 4818 CK, Netherlands|HagaZiekenhuis, Den Haag, 2545 CH, Netherlands|Gemini Ziekenhuis, Den Helder, 1782 GZ, Netherlands|Albert Schweitzer Ziekenhuis Amstelwijck, Dordrecht, 3317 NM, Netherlands|Catharina Ziekenhuis, Eindhoven, 5632 EJ, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, 8934 AD, Netherlands|Leids Universitair Medisch Centrum, Leiden, 2333 ZA, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, 6229 HX, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, 3435 CM, Netherlands|Erasmus Medical Center, Rotterdam, 3015 GD, Netherlands|Erasmus Medisch Centrum, Rotterdam, 3015 GD, Netherlands|Twee Steden Ziekenhuis Tilburg, Tilburg, 5042 AD, Netherlands|VieCuri Medisch Centrum Venlo, Venlo, 5912 BL, Netherlands|Isala Klinieken, Zwolle, 8025 AB, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, 80-952, Poland|Regionalny Osrodek Onkologiczny WSS im. M. Kopernika, Lodz, 93-509, Poland|ZOZ MSWiA z Warminsko- Mazurskim Centrum Onkologii, Olsztyn, 10-228, Poland|NZOZ Olsztynski Osr. Onkologiczny Kopernik Sp.z o.o, Olsztyn, 10-513, Poland|SPZOZ Wojewodzki Szpital Specjalistyczny nr 3 w Rybniku, Rybnik, 44-200, Poland|Centrum Onkologii-Instytut im.Marii Sklodowskiej-Curie, Warszawa, 02-781, Poland|4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ, Wroclaw, 50-981, Poland|Moscow Oncology Clinical Dispensary 1, Moscow, 105005, Russian Federation|Medical Radiology Research Centre RAMS, Obninsk, 249036, Russian Federation|State Institution of Heath Omsk Regional Oncology Dispensary, Omsk, 644013, Russian Federation|Russian Scientific Center for Radiology and Surgical Technol, St. Petersburg, Pesochny Vlg Saint Petersburg, 197758, Russian Federation|NSHI Dorozhnaya Clinical Hospital of OAO Russian Railways, Rostov-on-Don, 344011, Russian Federation|Oncology Dispensary 2 of Krasnodar Region, Sochi, 354057, Russian Federation|Yaroslavl Regional Clinical Oncology Hospital, Yaroslavl, 150054, Russian Federation|Groote Schuur Hospital, Cape Town, W Cape, 7925, South Africa|The Oncology Centre Durban, Durban, KZ-Natal, 4091, South Africa|Westridge Medical Centre, Durban, KZ-Natal, 4091, South Africa|Netcare Oncology and Interventional Centre, Goodwood, W Cape, 7460, South Africa|Dr. H. Malan, Polokwane, 699, South Africa|Pretoria Urology Hospital, Pretoria, 0083, South Africa|Hospital del Mar, Barcelona, 08003, Spain|Hospital Durán i Reynals - Instituto Catalàn de Oncologìa ICO, Hospitalet de Llobregat, Barcelona, 08907, Spain|Hospital Arnau de Vilanova, Lérida, 25198, Spain|Hospital 12 de Octobre, Madrid, 28041, Spain|HCU Virgen de la Victoria, Malaga, 29010, Spain|Clinica Universitaria de Navarra, Pamplona, 31008, Spain|Hospital Mutua de Terrassa, Terrassa (Barcelona), 08221, Spain|Hospital Clinico Universitario de Valencia, Valencia, 46010, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain|Lanssjukhuset Ryhov, Jönköping, 55185, Sweden|Norrlands Universitetssjukhus, Umeå, 90185, Sweden|Centrallasarettet Vasteras, Västerås, 721 89, Sweden|Clatterbridge Centre for Oncology NHS Trust, Bebington, Wirral, CH63 4JY, United Kingdom|Addenbrookes Hospital, Cambridge, CB2 0QQ, United Kingdom|Royal Surrey County Hospital, Guildford, GU2 7XX, United Kingdom|Guy's and St Thomas' Hospital - London, London, SE1 9RT, United Kingdom|St George's Hospital, London, SW17 0QT, United Kingdom|Royal Marsden Hospital, London, SW3 6JJ, United Kingdom|Christie NHS Trust Hospital, Manchester, M20 4BX, United Kingdom|Nottingham City Hospital, Nottingham, NG5 1PB, United Kingdom|Northern Lincolnshire and Goole Hospitals NHS Foundation Trust, Scunthorpe, DN15 7BH, United Kingdom|Royal Marsden Hospital, Sutton, SM2 5PT, United Kingdom",
